GILD
GILEAD SCIENCES, INC.
Nasdaq: GILD · Foster City, CA · Healthcare
$145.65-0.99 (-0.68%)Closed
Market Cap$180.75B
Cash$5.41Bmost recent
Runwayprofitable
P/E (TTM)21.5EPS $6.78
52-Wk Range$108.50 – $153.91
Avg Volume7.0M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$145.65+89.4%
Pipeline

Drug candidates sponsored by GILEAD SCIENCES · ClinicalTrials.gov

70 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4EFV+TDF
HIV Infections
Completed
2005-06past
1
Phase 4Ranolazine
Chronic Angina
Completed
2011-01past
1
Phase 4emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
HIV Infection
Completed
2011-03past
1
Phase 4Ambisome
Leukemia
Completed—1
Phase 3Viread (tenofovir disoproxil fumarate)
HIV Infections
Completed
2001-12past
1
Phase 3Emtricitabine (FTC)
HIV Infections
Completed
2005-02past
1
Phase 3Tenofovir DF
HIV Infections
Completed
2009-04-06past
2
Phase 3Ambrisentan
Pulmonary Hypertension+1 more
Completed
2010-03past
2
Phase 3Regadenoson
Coronary Artery Disease+1 more
Completed
2010-04past
2
Phase 3Aztreonam for Inhalation Solution (AZLI)
Cystic Fibrosis
Completed
2010-05past
1
Phase 3Elvitegravir
HIV Infection
Completed
2010-12past
1
Phase 3COBI
HIV+1 more
Completed
2011-11past
1
Phase 3E/C/F/TDF
Acquired Immunodeficiency Syndrome+1 more
Completed
2013-01past
1
Phase 3AZLI
Bronchiectasis+2 more
Completed
2015-01past
3
Phase 3Placebo
Indolent Non-Hodgkin's Lymphomas+1 more
Completed
2016-05-18past
2
Phase 3FTC/RPV/TAF
HIV-1 Infection
Completed
2016-06-22past
1
Phase 3SOF/VEL/VOX
Hepatitis C Virus Infection
Completed
2016-10-12past
2
Phase 3TAF
HBV+1 more
Completed
2017-03-21past
1
Phase 2EVG
Acquired Immune Deficiency Syndrome (AIDS)+1 more
Terminated
2017-11-03past
1
Phase 3Filgotinib
Rheumatoid Arthritis
Completed
2018-03-20past
1
Phase 3SOF
Chronic Hepatitis C+1 more
Completed
2018-06-21past
2
Phase 3LDV/SOF
Chronic Hepatitis C Virus+4 more
Completed
2018-11-12past
10
Phase 3SOF/VEL
Hepatitis C Virus Infection
Completed
2019-11-19past
5
Phase 3E/C/F/TAF
HIV+5 more
Completed
2020-05-11past
5
Phase 3Remdesivir
COVID-19
Completed
2023-02-10past
2
Phase 3Seladelpar 10 mg
Primary Biliary Cholangitis
Completed
2023-08-11past
1
Phase 3Sacituzumab Govitecan-hziy
Metastatic Breast Cancer
Completed
2023-10-20past
1
Phase 3Oral Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Active, not recruiting
2024-05-27past
1
Phase 3Bictegravir
HIV-1-infection
Active, not recruiting
2025-10-27past
1
Phase 3Lenacapavir Injection
HIV Pre-exposure Prophylaxis
Active, not recruiting
2028-09
1
Phase 3Seladelpar
Primary Biliary Cholangitis
Recruiting
2030-08
1
Phase 1milatuzumab
Multiple Myeloma+2 more
Completed
2009-06past
1
Phase 1GS-9219
Non-Hodgkin's Lymphoma+2 more
Terminated
2010-07past
1
Phase 2Tegobuvir (GS-9190)
Hepatitis C, Chronic
Completed
2013-01past
1
Phase 2GS-9190
Chronic Hepatitis C Infection
Completed
2013-01past
1
Phase 2Sofosbuvir
Hepatitis C, Chronic
Completed
2013-04past
1
Phase 1IMMU-107 (hPAM4)
Pancreatic Cancer
Completed
2013-07past
1
Phase 2VOX
Hepatitis C Virus Infection
Completed
2015-09-21past
1
Phase 2Tenofovir disoproxil fumarate
Chronic Hepatitis B+1 more
Completed
2016-02-17past
3
Phase 2Vesatolimod
Chronic Hepatitis B
Completed
2016-05-11past
1
Phase 2Presatovir
Respiratory Syncytial Virus Infection
Completed
2017-04-17past
2
Phase 2GS-9674
Nonalcoholic Steatohepatitis (NASH)
Completed
2018-01-09past
1
Phase 1Idelalisib
Indolent Non-Hodgkin's Lymphoma+4 more
Completed
2019-03-26past
2
Phase 2Tirabrutinib
Chronic Lymphocytic Leukemia
Completed
2019-06-17past
1
Phase 2Inarigivir Soproxil
Chronic Hepatitis B
Terminated
2020-01-20past
1
Phase 2GS-5718
Rheumatoid Arthritis
Withdrawn
2023-02past
1
Phase 2ISL
HIV-1 Infection
Active, not recruiting
2023-12-19past
1
Phase 2Magrolimab
Triple-Negative Breast Cancer
Terminated
2024-10-08past
1
Phase 2Efavirenz
HIV Infections
Completed—1
Phase 2BSF 208075
Pulmonary Hypertension
Completed—1
Phase 2Nelfinavir mesylate
HIV Infections
Completed—1
Phase 2Cidofovir
Cytomegalovirus Retinitis+1 more
Completed—1
Phase 1GS-9411
Cystic Fibrosis+2 more
Completed
2009-09past
1
Phase 1AB0024
Neoplasms
Completed
2012-03past
1
Phase 1GS-5806
RSV Infection
Completed
2013-04past
1
Phase 1GS-5737
Cystic Fibrosis+1 more
Terminated
2013-06past
1
Phase 1Voxilaprevir
Hepatitis C Virus Infection
Completed
2014-12-22past
1
Phase 1GS-9901
Follicular Lymphoma+3 more
Terminated
2015-08past
1
Phase 1Eleclazine
Long QT Syndrome
Completed
2016-04-22past
1
Phase 1Andecaliximab
Pancreatic Cancer+4 more
Completed
2019-04-23past
1
Phase 1GS-3583
Advanced Solid Tumors
Terminated
2022-11-07past
1
Phase 1GS-4571
Weight Management
Recruiting
2026-11
1
Phase 1B/F/TAF
HIV-1-infection
Active, not recruiting
2028-03
1
Phase 1GS-2426
Advanced Solid Tumors
Recruiting
2029-01
1
Phase 1Adefovir dipivoxil
HIV Infections
Completed—1
N/AUnnamed
Cystic Fibrosis
Completed
2016-12past
1
N/AUnnamed
Hepatitis C, Chronic
Completed
2017-03-28past
1
N/AGS-4774
Chronic Hepatitis B
Terminated
2017-08-14past
1
N/AUnnamed
HIV Infection
Completed
2018-03-13past
1
N/AIMMU-132
Metastatic Triple-Negative Breast Carcinoma
Approved For Marketing—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.